Summary of adverse events
| . | Dose-escalation cohort, n = 11 (%) . | Dose-expansion cohort, n = 16 (%) . | RP2/3D cohort, N = 22 (%) . | Total, N = 27 (%) . |
|---|---|---|---|---|
| Any AE | 11 (100) | 15 (94) | 21 (95) | 26 (96) |
| Drug-related AE | 9 (82) | 13 (81) | 18 (82) | 22 (81) |
| Grade ≥3 AE | 9 (82) | 13 (81) | 18 (82) | 22 (81) |
| Drug-related grade ≥3 AE | 6 (55) | 5 (31) | 8 (36) | 11 (41) |
| Serious AE | 8 (73) | 9 (56) | 12 (55) | 17 (63) |
| Drug-related serious AE | 3 (27) | 1 (6) | 2 (9) | 4 (15) |
| AEs resulting in drug discontinuation | 3 (27) | 2 (13) | 3 (14) | 5 (19) |
| On-study deaths | 0 | 1 (6) | 1 (5) | 1 (4) |
| . | Dose-escalation cohort, n = 11 (%) . | Dose-expansion cohort, n = 16 (%) . | RP2/3D cohort, N = 22 (%) . | Total, N = 27 (%) . |
|---|---|---|---|---|
| Any AE | 11 (100) | 15 (94) | 21 (95) | 26 (96) |
| Drug-related AE | 9 (82) | 13 (81) | 18 (82) | 22 (81) |
| Grade ≥3 AE | 9 (82) | 13 (81) | 18 (82) | 22 (81) |
| Drug-related grade ≥3 AE | 6 (55) | 5 (31) | 8 (36) | 11 (41) |
| Serious AE | 8 (73) | 9 (56) | 12 (55) | 17 (63) |
| Drug-related serious AE | 3 (27) | 1 (6) | 2 (9) | 4 (15) |
| AEs resulting in drug discontinuation | 3 (27) | 2 (13) | 3 (14) | 5 (19) |
| On-study deaths | 0 | 1 (6) | 1 (5) | 1 (4) |